Get the Stockscreener App
4.53
1.57%
0.07
After Hours:
4.53
Coya Therapeutics Inc stock is traded at $4.53, with a volume of 107.17K.
It is up +1.57% in the last 24 hours and up +0.00% over the past month.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
See More
Previous Close:
$4.46
Open:
$4.45
24h Volume:
107.17K
Relative Volume:
0.58
Market Cap:
$106.26M
Revenue:
$7.95M
Net Income/Loss:
$-21.23M
P/E Ratio:
-3.7734
EPS:
-1.2005
Net Cash Flow:
$-11.90M
1W Performance:
+10.22%
1M Performance:
+0.00%
6M Performance:
-32.49%
1Y Performance:
-17.79%
1-Day Range:
$4.34
$4.54
1-Week Range:
$4.06
$4.585
52-Week Range:
$3.7101
$7.75
Coya Therapeutics Inc Stock (COYA) Company Profile
Name
Coya Therapeutics Inc
Sector
Industry
Phone
650.739.3939
Address
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
4.53 | 104.62M | 7.95M | -21.23M | -11.90M | -1.2005 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Lake Street | Buy |
| Dec-04-24 | Initiated | D. Boral Capital | Buy |
Coya Therapeutics Inc Stock (COYA) Latest News
COYA Options Volatility — NASDAQ:COYA - TradingView — Track All Markets
COYA Options Chain — NASDAQ:COYA - TradingView — Track All Markets
COYA PE Ratio & Valuation, Is COYA Overvalued - Intellectia AI
COYA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Volume Report: Is Coya Therapeutics Inc impacted by rising ratesTrade Analysis Report & High Accuracy Trade Alerts - baoquankhu1.vn
Coya Therapeutics Is Maintained at Buy by D. Boral Capital - Moomoo
Market Review: Is Coya Therapeutics Inc benefiting from innovation trends2026 Catalysts & Accurate Entry/Exit Alerts - baoquankhu1.vn
Coya Therapeutics (COYA) director receives 10,000 stock options at $4.53 - Stock Titan
New Coya Therapeutics (COYA) director Mark H. Pavao files initial Form 3 - Stock Titan
Stop Loss: Will Coya Therapeutics Inc outperform its industry peers2026 Bull vs Bear & Technical Pattern Based Signals - baoquankhu1.vn
Market Leaders: How do insiders feel about Coya Therapeutics Inc2026 Earnings Impact & Free High Return Stock Watch Alerts - baoquankhu1.vn
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS - Business Wire
Coya Therapeutics Announces Leadership Changes and New Director - The Globe and Mail
Coya Therapeutics founder steps down, adds new director By Investing.com - Investing.com Australia
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent - PharmiWeb.com
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director - BioSpace
COYA: Treg-focused therapies show promise in neurodegeneration, with pivotal trials underway - TradingView — Track All Markets
Investor Presentation (04/02/2026 00: 00 - marketscreener.com
Founder steps down as Coya Therapeutics (COYA) adds independent director Mark Pavao - Stock Titan
Coya Therapeutics founder steps down, adds new director - Investing.com
Monopar Therapeutics Inc (MNPR) Receives a Buy from Lake Street - The Globe and Mail
Portfolio Update: Is Coya Therapeutics Inc forming higher highs and higher lows2026 Market Mood & Reliable Intraday Trade Plans - baoquankhu1.vn
Death Cross: How do insiders feel about Coya Therapeutics IncExit Point & Daily Profit Focused Screening - baoquankhu1.vn
Brokerages Set Coya Therapeutics, Inc. (NASDAQ:COYA) PT at $16.00 - Defense World
Aug Sentiment: Is Coya Therapeutics Inc forming higher highs and higher lows2026 Retail Activity & Technical Buy Zone Confirmation - baoquankhu1.vn
D. Boral Capital Maintains Coya Therapeutics (COYA) Buy Recommendation - MSN
Analysts Are Bullish on Top Healthcare Stocks: NRX Pharmaceuticals (NRXP), Rezolute (RZLT) - The Globe and Mail
BTIG Reiterates Coya Therapeutics (COYA) Buy Recommendation - MSN
HC Wainwright Analysts Decrease Earnings Estimates for COYA - marketbeat.com
What is HC Wainwright’s Estimate for COYA Q1 Earnings? - Defense World
Sell Signal: How much upside does Coya Therapeutics Inc have2026 Big Picture & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Coya Therapeutics (NASDAQ:COYA) Given “Buy” Rating at HC Wainwright - Defense World
ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President a - pharmiweb.com
What is HC Wainwright's Estimate for COYA Q1 Earnings? - MarketBeat
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO - BioSpace
Coya Therapeutics' (COYA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Coya Therapeutics: Advancing Treg-Focused Pipeline with Near-Term Catalysts in ALS and FTD Supporting Buy Rating - TipRanks
Coya Therapeutics (COYA) Analyst Rating Reiterated at 'Buy' by H - GuruFocus
[EFFECT] Coya Therapeutics, In... | COYA SEC FilingForm EFFECT - Stock Titan
ALDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Coya Therapeutics (NASDAQ:COYA) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
CEO Moves: Can Coya Therapeutics Inc sustain earnings growthInflation Watch & Community Consensus Trade Alerts - baoquankhu1.vn
2.52M-share resale registration by Coya Therapeutics (NASDAQ: COYA) after Jan 2026 placement - stocktitan.net
Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK), Valneva (VALN) and Protagonist Therapeutics (PTGX) - The Globe and Mail
Coya Therapeutics (COYA): Analyst Jason Kolbert Maintains Buy Ra - GuruFocus
Analysts Offer Insights on Healthcare Companies: Immutep Ltd (OtherPRRUF), Coya Therapeutics, Inc. (COYA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy - Business Wire
Coya Therapeutics (COYA) Deepening Losses Challenge Bullish Growth Narrative After FY 2025 Results - simplywall.st
COYA SEC FilingsCoya Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Aggressive Treg-Modulating Immunology Strategy and Advancing Clinical Execution Underpin Buy Rating on Coya in ALS and FTD - TipRanks
Coya Therapeutics Inc Stock (COYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):